Both types of change in Wnt signalling have been linked to cancer. Therefore, a great deal of effort is being invested worldwide in developing therapeutic agents that function by fine-tuning the ...

ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid ...

Scientists suggest understanding ecDNA’s role in pancreatic cancer could potentially guide future strategies for making ...

Pancreatic cancer is one of the deadliest cancers worldwide, with a five-year survival rate of 13%. This poor prognosis stems ...

"We knew the tumor's surroundings could drive changes, but not that WNT signaling could so directly rewrite DNA," Bailey adds ...

The disclosure of a new candidate by Dewpoint Therapeutics Inc. was the latest in the percolating beta-catenin/Wnt space, where a handful of firms have been making progress.

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

The protocol aims to deepen our understanding of stenoparib’s clinical benefit in a well-defined ovarian cancer patient population while also assessing its potential impact on the Wnt pathway ...